CARsgen’s Satri-cel Shows Promising Phase II Results in Advanced Cancer Treatment

CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has shared an announcement.

CARsgen Therapeutics Holdings Limited announced the publication of pivotal Phase II clinical trial results for its Claudin18.2-specific CAR T-cell product candidate, satricabtagene autoleucel (satri-cel), in The Lancet and presented at the 2025 ASCO Annual Meeting. The trial focused on patients with advanced gastric/gastroesophageal junction cancer who had not responded to previous treatments. Satri-cel has received various designations, including Priority Review and Breakthrough Therapy Designation from China’s NMPA and Regenerative Medicine Advanced Therapy designation from the U.S. FDA, highlighting its potential impact on treating Claudin18.2-positive tumors.

The most recent analyst rating on (HK:2171) stock is a Sell with a HK$8.96 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.

More about CARsgen Therapeutics Holdings Ltd.

CARsgen Therapeutics Holdings Limited is a biopharmaceutical company specializing in the development of innovative CAR T-cell therapies aimed at addressing unmet clinical needs in hematologic malignancies, solid tumors, and autoimmune diseases. The company has comprehensive capabilities in CAR T-cell research and development, including target discovery, preclinical research, clinical development, and commercial-scale production. CARsgen is committed to improving the safety and efficacy of CAR T-cell therapies and aims to be a global leader in providing innovative cell therapies.

Average Trading Volume: 3,990,938

Technical Sentiment Signal: Buy

Current Market Cap: HK$11.66B

For detailed information about 2171 stock, go to TipRanks’ Stock Analysis page.